MedTrace Logo

Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia

NCT01189279 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2013-08-30

Study results available
· View outcomes & findings →

Summary

This study will investigate the safety, tolerability, and pharmacokinetics of new formulation of bimatoprost following topical application in patients with alopecia. Two formulations of bimatoprost will be investigated in Part 1 and a third formulation of bimatoprost will be investigated in Part 2. Part 2 will begin after Part 1 has completed.

Conditions

  • Alopecia
  • Alopecia, Androgenetic
  • Baldness

Interventions

DRUG

bimatoprost Formulation A

bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.

DRUG

bimatoprost Formulation B

bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.

DRUG

bimatoprost Formulation C

bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-01-31
Completion
2011-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01189279 on ClinicalTrials.gov